Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | Clinical factors scoring system for CAR-T patient selection in R/R multiple myeloma

Beth Faiman • 26 Aug 2022
IMS 2022
Multiple Myeloma CAR-T Ciltacabtagene autoleucel Idecabtagene vicleucel

Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, Cleveland Clinic, Cleveland, OH, discusses the challenges in access to commercial CAR-T therapies for patients with relapsed/refractory (R/R) multiple myeloma in the US, outlining a novel clinical factors scoring system to better allocate slots to patients. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Beth Faiman

0:57
The importance of shared decision making in multiple myeloma
Beth Faiman • 26 Aug 2022
0:52
Differences in approaches to managing patients with multiple myeloma vs amyloidosis
Beth Faiman • 26 Aug 2022
0:56
The Cleveland Clinic Survivor Care Program Model for patients with multiple myeloma
Beth Faiman • 26 Aug 2022
0:38
Challenges in managing patients with multiple myeloma: the nursing perspective
Beth Faiman • 26 Aug 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals